{"id":"potassium-phosphates","rwe":[],"_fda":{"id":"9256cc7f-e593-4224-8b44-19e8d01d2cb4","set_id":"125121b8-bc4c-44ee-906e-e72f652a5aa6","openfda":{"upc":["0380830169192"],"unii":["CI71S98N1Z","4J9FJ0HL51"],"route":["INTRAVENOUS"],"rxcui":["1928569"],"spl_id":["9256cc7f-e593-4224-8b44-19e8d01d2cb4"],"brand_name":["POTASSIUM PHOSPHATES"],"spl_set_id":["125121b8-bc4c-44ee-906e-e72f652a5aa6"],"package_ndc":["80830-1691-3","80830-1691-9"],"product_ndc":["80830-1691"],"generic_name":["POTASSIUM PHOSPHATE, MONOBASIC POTASSIUM PHOSPHATE, DIBASIC INJECTION,"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["POTASSIUM PHOSPHATE, DIBASIC","POTASSIUM PHOSPHATE, MONOBASIC"],"manufacturer_name":["Amneal Pharmaceuticals Private Limited"],"application_number":["ANDA216344"],"is_original_packager":[true]},"version":"1","pregnancy":["8.1 Pregnancy Risk Summary Administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with potassium phosphates injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo-Fetal Risk Phosphorus is an essential mineral element. Parenteral supplementation with potassium phosphates should be considered if a pregnant woman’s requirements cannot be fulfilled by oral or enteral intake."],"overdosage":["10 OVERDOSAGE Hyperphosphatemia Administration of excessive doses of intravenous potassium phosphates in intravenous fluids as a single-dose ranging from approximately 50 mmol to 270 mmol phosphorus and/or at rapid infusion rates (over 1 hour to 3 hours) has resulted in death, cardiac arrest, cardiac arrhythmia (including QT prolongation), hyperkalemia, hyperphosphatemia, seizures and tetany. Hyperphosphatemia is particularly a risk in patients with renal failure. Hyperphosphatemia leads in turn to hypocalcemia, which may be severe and to ectopic calcification, particularly in patients with initial hypercalcemia. Tissue calcification may cause hypotension and organ damage and result in acute renal failure. Hyperkalemia Excessive administration of phosphates given as potassium salts may also cause hyperkalemia. Manifestations of hyperkalemia include: Disturbances in cardiac conduction and arrhythmias, including bradycardia, heart block, asystole, ventricular tachycardia, ventricular fibrillation. Hypotension. Muscle weakness including paresthesia, muscular and respiratory paralysis. Management In the event of overdosage, discontinue infusions containing potassium phosphates immediately and institute general supportive measures, including ECG monitoring, laboratory monitoring and correction of serum electrolyte concentrations, especially potassium, phosphorus, calcium and magnesium."],"description":["11 DESCRIPTION Potassium Phosphates Injection, USP, a phosphorus replacement product containing phosphorus 3 mmol/mL and potassium 4.4 mEq/mL. It is a sterile clear, colorless, non-pyrogenic, concentrated solution containing a mixture of monobasic potassium phosphate, USP and dibasic potassium phosphate, USP in water for injection. It is supplied as a 15 mL single-dose vial. Monobasic potassium phosphate, USP is chemically designated potassium dihydrogen phosphate. The molecular formula is KH 2 PO 4 , molecular weight is 136.084 g/mol and the structural formula is as below: It appears as colorless crystals or white granular or crystalline powder. It is freely soluble in water and practically insoluble in alcohol. Dibasic potassium phosphate, USP is chemically designated dipotassium hydrogen phosphate. The molecular formula is K 2 HPO 4 , molecular weight is 174.18 g/mol and the structural formula is as below: It appears as colorless crystals or white granular or crystalline powder. It is freely soluble in water. Each mL of Potassium Phosphates Injection, USP contains monobasic potassium phosphate USP, 224 mg; dibasic potassium phosphate USP, 236 mg and water for injection. Each mL contains 3 mmol phosphorus (equivalent to 93 mg phosphorus) and 4.4 mEq potassium (equivalent to 170 mg of potassium). Note: 1 mmol of phosphorus is equal to 1 mmol phosphate. The pH is 6.0 to 7.0. This product contains no more than 900 mcg/L of aluminum [ see Warnings and Precautions (5.5) ] . The osmolarity is 7.4 mOsmol/mL (calc). The solution is administered after dilution or admixing by the intravenous route. 1 2"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Potassium Phosphates Injection, USP is a sterile clear, colorless solution supplied as phosphorus 3 mmol/mL and potassium 4.4 mEq/mL as shown: Product Code Unit of Sale Strength Each 1691 NDC 80830-1691-9 Carton containing 10 units Phosphorus 45 mmol/15 mL and Potassium 66 mEq/15 mL NDC 80830-1691-3 15 mL single-dose, polypropylene vial Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. For storage of admixed solution, see Dosage and Administration 2.1 , 2.3 ."],"effective_time":"20250430","adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Aluminum Toxicity [see Warnings and Precautions (5.5) ] Hypomagnesemia [see Warnings and Precautions (5.6) ] Vein Damage and Thrombosis [see Warnings and Precautions (5.7) ] The following adverse reactions in Table 5 have been reported in clinical studies or post-marketing reports in patients receiving intravenously administered potassium phosphates. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Table 5: Adverse Reactions Reported in Clinical Studies or Post-marketing Reports with Intravenous Potassium Phosphates System Organ Class Adverse Reactions Metabolism and Nutrition Disorders pulmonary embolism due to pulmonary vascular precipitates [see Warnings and Precautions (5.2) ], hyperkalemia [see Warnings and Precautions (5.3) ] , hyperphosphatemia [see Warnings and Precautions (5.4) ], hypocalcemia [see Warnings and Precautions (5.5) ] , hypovolemia and osmotic diuresis Cardiac Disorders hypotension, arrhythmia, heart block, cardiac arrest, bradycardia, chest pain, ECG changes [see Warnings and Precautions (5.1) ] and edema Respiratory, Thoracic and Mediastinal Disorders dyspnea [see Warnings and Precautions (5.2) ] Renal and Urinary Disorders acute phosphate nephropathy (i.e., nephrocalcinosis with acute kidney injury), decreased urine output and transition to chronic kidney disease [see Warnings and Precautions (5.4) ] Gastrointestinal Disorders diarrhea, stomach pain Musculoskeletal and Connective Tissue Disorders weakness Nervous System Disorders confusion, lethargy, paralysis, paresthesia Adverse reactions include hyperkalemia, hyperphosphatemia, hypocalcemia and hypomagnesemia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ."],"contraindications":["4 CONTRAINDICATIONS Potassium phosphates injection is contraindicated in patients with: Hyperkalemia [see Warning and Precautions (5.3) ]. Severe renal impairment (eGFR less than 30 mL/min/1.73 m 2 ) or end stage renal disease [see Warning and Precautions (5.3) ] . Hyperphosphatemia [see Warning and Precautions (5.4) ]. Hypercalcemia or significant hypocalcemia [see Warning and Precautions (5.4) ] . Hyperkalemia. ( 4 ) Hyperphosphatemia. ( 4 ) Hypercalcemia or significant hypocalcemia. ( 4 ) Severe renal impairment (eGFR less than 30 mL/min/1.73 m 2 ) or end stage renal disease. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Use of Other Medications that Increase Potassium : Avoid use in patients receiving such products. If use cannot be avoided, closely monitor serum potassium concentrations. ( 5.3 , 7.1 ) 7.1 Other Products that Increase Serum Potassium Administration of potassium phosphates injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3) ] . Avoid use of potassium phosphates injection in patients receiving such products. If use cannot be avoided, closely monitor serum potassium concentrations [see Dosage and Administration (2.2 , 2.4) ] ."],"how_supplied_table":["
Product CodeUnit of SaleStrengthEach
1691NDC 80830-1691-9 Carton containing 10 unitsPhosphorus 45 mmol/15 mL andPotassium 66 mEq/15 mLNDC 80830-1691-315 mL single-dose, polypropylene vial
"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Phosphorus in the form of organic and inorganic phosphate has a variety of biochemical functions in all organs and tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis and bone mineralization. 12.3 Pharmacokinetics Distribution Approximately 85% of serum phosphates is free and ultra-filterable and 15% is protein-bound. Elimination Intravenously infused phosphates not taken up by the tissues are excreted almost entirely in the urine. Serum phosphorus is believed to be filterable by the renal glomeruli and the major portion of filtered phosphorus (greater than 80%) is actively reabsorbed by the tubules."],"indications_and_usage":["1 INDICATIONS AND USAGE Potassium phosphates injection is indicated as a source of phosphorus: in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. Potassium phosphates injection is a phosphorus replacement product indicated as a source of phosphorus: in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. ( 1 ) for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Serious Cardiac Adverse Reactions with Undiluted, Bolus, or Rapid Intravenous Administration : Administer only after dilution or admixing; do not exceed the recommended infusion rate. Continuous electrocardiographic (ECG) monitoring may be needed during infusion. ( 2.2 , 5.1 ) Pulmonary Embolism due to Pulmonary Vascular Precipitates : If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. ( 5.2 ) Hyperkalemia : Increased risk in patients with renal impairment, severe adrenal insufficiency, or treated with drugs that increase potassium. Patients with cardiac disease may be more susceptible. Do not exceed the maximum daily amount of potassium or the recommended infusion rate. Continuous ECG monitoring may be needed during infusion. ( 5.3 , 7.1 ) Hyperphosphatemia and Hypocalcemia : Monitor serum phosphorus and calcium concentrations during and following infusion. ( 5.4 ) Aluminum Toxicity : Increased risk in patients with renal impairment, including preterm infants. ( 5.5 , 8.4 ) Hypomagnesemia : Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor serum magnesium concentrations during treatment. ( 5.6 ) Vein Damage and Thrombosis : Infuse concentrated or hypertonic solutions through a central catheter. ( 2.1 , 2.3 , 5.7 ) 5.1 Serious Cardiac Adverse Reactions with Undiluted, Bolus or Rapid Intravenous Administration Intravenous administration of potassium phosphates to correct hypophosphatemia in single-doses of phosphorus 50 mmol and greater and/or at rapid infusion rates (over 1 hour to 3 hours) in intravenous fluids has resulted in death, cardiac arrest, cardiac arrhythmia (including QT prolongation), hyperkalemia, hyperphosphatemia and seizures [see Overdosage (10) ]. In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid “intravenous push” has resulted in cardiac arrest, cardiac arrhythmias, hypotension and death. Potassium phosphates injection is for intravenous infusion only after dilution or admixing . The maximum initial or single-dose of potassium phosphates injection in intravenous fluids to correct hypophosphatemia is phosphorus 45 mmol (potassium 66 mEq). The recommended infusion rate for administration through a peripheral venous catheter is approximately phosphorus 6.8 mmol/hour (potassium 10 mEq/hour). Continuous electrocardiographic (ECG) monitoring is recommended for higher infusion rates [see Dosage and Administration (2.1 , 2.2) ] . 5.2 Pulmonary Embolism due to Pulmonary Vascular Precipitates Pulmonary vascular emboli and pulmonary distress related to precipitates in the pulmonary vasculature have been described in patients receiving admixed products containing calcium and phosphate or parenteral nutrition. The cause of precipitate formation has not been determined in all cases; however, in some fatal cases, pulmonary emboli occurred as a result of calcium phosphate precipitates. Precipitation has occurred following passage through an in-line filter; in vivo precipitate formation may also have occurred. If signs of pulmonary distress occur, stop the parenteral nutrition infusion and initiate a medical evaluation. In addition to inspection of the solution [see Dosage and Administration (2.3) ] , the infusion set and catheter should also periodically be checked for precipitates. 5.3 Hyperkalemia Potassium phosphates injection may increase the risk of hyperkalemia, including life-threatening cardiac events, especially when administered in excessive doses, undiluted or by rapid intravenous infusion [see Warnings and Precautions (5.1) ] . Patients with severe renal impairment and end stage renal disease are at increased risk of developing life-threatening hyperkalemia, when administered intravenous potassium [see Contraindications (4) ] . Other patients at increased risk of hyperkalemia include those with severe adrenal insufficiency or treated concurrently with other drugs that cause or increase the risk of hyperkalemia [see Drug Interactions (7.1) ] . Patients with cardiac disease may be more susceptible to the effects of hyperkalemia. Consider the amount of potassium from all sources when determining the dose of potassium phosphates injection and do not exceed the maximum age-appropriate recommended daily amount of potassium. In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m 2 to < 60 mL/min/1.73 m 2 ), start at the low end of the dose range and monitor serum potassium, phosphorus, calcium and magnesium concentrations [see Dosage and Administration (2.2 , 2.4 ), Use in Specific Populations (8.6) ] . When administering potassium phosphates injection in intravenous fluids to correct hypophosphatemia, check the serum potassium concentration prior to administration. If the potassium concentration is 4 mEq/dL or more, do not administer potassium phosphates injection and use an alternative source of phosphorus [see Dosage and Administration (2.1) ] . The maximum initial or single-dose of potassium phosphates injection in intravenous fluids to correct hypophosphatemia is phosphorus 45 mmol (potassium 66 mEq). The recommended infusion rate of potassium through a peripheral venous catheter is 10 mEq/hour. Continuous electrocardiographic (ECG) monitoring is recommended for higher infusion rates of potassium [see Dosage and Administration (2.2) ] . 5.4 Hyperphosphatemia and Hypocalcemia Hyperphosphatemia can occur with intravenous administration of potassium phosphates, especially in patients with renal impairment. Hyperphosphatemia can cause the formation of insoluble calcium phosphorus products with consequent hypocalcemia, neurological irritability with tetany, nephrocalcinosis with acute kidney injury and more rarely, cardiac irritability with arrhythmias. Obtain serum calcium concentrations prior to administration and normalize the calcium before administering potassium phosphates injection. Potassium phosphates injection is contraindicated in patients with hyperphosphatemia and/or hypercalcemia [see Contraindications (4) ] . Monitor serum phosphorus and calcium concentrations during treatment with potassium phosphates injection [see Dosage and Administration (2.2 , 2.4) ] . 5.5 Aluminum Toxicity Potassium phosphates injection contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impairment. Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature and they require large amounts of calcium and phosphate containing solutions, which also contain aluminum. Patients with renal impairment, including preterm infants, who receive greater than 4 to 5 mcg/kg/day of parenteral aluminum can accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Exposure to aluminum from potassium phosphates injection is no more than 0.6 mcg/kg/day when patients are administered the recommended dosage [see Dosage and Administration (2.4) , Description (11) ] . When prescribing potassium phosphates injection for use in parenteral nutrition solutions containing other small volume parenteral products, the total daily patient exposure to aluminum from the admixture should be considered and maintained at no more than 5 mcg/kg/day [see Use in Specific Populations (8.4) ] . 5.6 Hypomagnesemia Intravenous infusion of phosphate has been reported to cause a decrease in serum magnesium (and calcium) concentrations when administered to patients with hypercalcemia and diabetic ketoacidosis. Monitor serum magnesium concentrations during treatment. 5.7 Vein Damage and Thrombosis Potassium phosphates injection must be diluted and administered in intravenous fluids or used as an admixture in parenteral nutrition. It is not for direct intravenous infusion. The infusion of hypertonic solutions into a peripheral vein may result in vein irritation, vein damage and/or thrombosis. The primary complication of peripheral administration is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible and initiate appropriate medical treatment if thrombophlebitis develops. When administered peripherally in intravenous fluids to correct hypophosphatemia, a generally recommended maximum concentration is phosphorus 6.8 mmol/100 mL (potassium 10 mEq/100 mL) [see Dosage and Administration (2.1) ]. Parenteral nutrition solutions with an osmolarity of 900 mOsmol/L or greater must be infused through a central catheter [see Dosage and Administration (2.3) ] . 5.8 Laboratory Monitoring Monitor serum phosphorus, potassium, calcium and magnesium concentrations during treatment [see Dosage and Administration (2.2 , 2.4) ] ."],"adverse_reactions_table":["
System Organ Class Adverse Reactions
Metabolism and Nutrition Disorders pulmonary embolism due to pulmonary vascular precipitates [see Warnings and Precautions (5.2)], hyperkalemia [see Warnings and Precautions (5.3)], hyperphosphatemia [see Warnings and Precautions (5.4)], hypocalcemia [see Warnings and Precautions (5.5)], hypovolemia and osmotic diuresis
Cardiac Disorders hypotension, arrhythmia, heart block, cardiac arrest, bradycardia, chest pain, ECG changes [see Warnings and Precautions (5.1)] and edema
Respiratory, Thoracic and Mediastinal Disordersdyspnea [see Warnings and Precautions (5.2)]
Renal and Urinary Disorders acute phosphate nephropathy (i.e., nephrocalcinosis with acute kidney injury), decreased urine output and transition to chronic kidney disease [see Warnings and Precautions (5.4)]
Gastrointestinal Disorders diarrhea, stomach pain
Musculoskeletal and Connective Tissue Disorders weakness
Nervous System Disorders confusion, lethargy, paralysis, paresthesia
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Inform patients, caregivers or home healthcare providers of the following risks of potassium phosphates injection: Serious Cardiac Adverse Reactions with Undiluted, Bolus or Rapid Intravenous Administration [see Warnings and Precautions (5.1) ] . Pulmonary Embolism due to Pulmonary Vascular Precipitates [see Warnings and Precautions (5.2) ] . Hyperkalemia [see Warnings and Precautions (5.3) ] . Hyperphosphatemia and Hypocalcemia [see Warnings and Precautions (5.4) ]. Aluminum toxicity [see Warnings and Precautions (5.5) ] . Hypomagnesemia [see Warnings and Precautions (5.6) ] . Vein Damage and Thrombosis [see Warnings and Precautions (5.7) ] . Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Ahmedabad 382110, INDIA Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 04-2025-00 Novaplus is a registered trademark of Vizient Inc. 3"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Administer intravenously only after dilution or admixing in a larger volume of fluid. ( 2.1 ) Potassium phosphates injection provides phosphorus 3 mmol/mL (potassium 4.4 mEq/mL). ( 2.2 , 2.4 ) Monitor serum phosphorus, potassium, calcium and magnesium concentrations. ( 2.2 , 2.4 ) See full prescribing information for instructions on preparation and administration. ( 2.1 , 2.3 ) Recommended Dosage for Correction of Hypophosphatemia in Intravenous Fluids Potassium phosphates injection is only for administration to a patient with a serum potassium concentration less than 4 mEq/dL; otherwise, use an alternative source of phosphorus. ( 2.1 ) The dosage is dependent upon the individual needs of the patient and the contribution of phosphorus and potassium from other sources. ( 2.2 ) See full prescribing information for recommendations on initial or single dosing, repeated dosing, concentration and infusion rate. ( 2.1 , 2.2 ) Recommended Dosage for Administration in Parenteral Nutrition Individualize the dosage based upon the patient’s clinical condition, nutritional requirements and the contribution of oral or enteral phosphorus and potassium intake. ( 2.4 ) See full prescribing information for recommendations for daily and maximum dosage. ( 2.4 ) 2.1 Preparation and Administration in Intravenous Fluids to Correct Hypophosphatemia Preparation Potassium phosphates injection is for intravenous infusion into a central or peripheral vein only after dilution . Using aseptic technique, withdraw the required amount from the vial and add to 0.9% Sodium Chloride Injection, USP (normal saline) or 5% Dextrose Injection, USP (D5W). For adults and pediatric patients 12 years of age and older a total volume of 100 mL or 250 mL is recommended. For pediatric patients less than 12 years of age, use the smallest recommended volume, considering daily fluid requirements and the maximum concentration for peripheral and central administration shown in Table 1. The concentration of the diluted solution should take into consideration the age of the patient, the amounts of phosphorus and potassium in the dose and is dependent upon whether administration will be through a peripheral or central venous catheter. The recommended maximum concentrations are shown in Table 1: Table 1: Maximum Recommended Concentration of Potassium Phosphates Injection by Age and Route of Administration (Peripheral vs. Central) Patient Population Peripheral Venous Catheter Central Venous Catheter Adults and Pediatric Patients 12 Years of Age and Older phosphorus 6.8 mmol/100 mL (potassium 10 mEq/100 mL) phosphorus 18 mmol/100 mL (potassium 26.4 mEq/100 mL) Pediatric Patients Less than 12 Years of Age phosphorus 0.27 mmol/10 mL (potassium 0.4 mEq/10 mL) phosphorus 0.55 mmol/10 mL (potassium 0.8 mEq/10 mL) Visually inspect the solution for particulate matter and discoloration before and after dilution and prior to administration. Do not administer unless solution is clear and seal on the vial is intact. Administration Check serum potassium and calcium concentrations prior to administration. Normalize the calcium before administering potassium phosphates injection [see Contraindications (4) , Warnings and Precautions (5.3 , 5.4) ] . Potassium phosphates injection is only for administration to a patient with a serum potassium concentration less than 4 mEq/dL [see Warnings and Precautions (5.3) ] . If the potassium concentration is 4 mEq/dL or more, use an alternative source of phosphorus. Do not infuse with calcium-containing intravenous fluids [see Warnings and Precautions (5.4) ] . The rate of administration may be dependent on the patient and the specific institution policy [see Dosage and Administration (2.2) ] . Storage and Stability Single-Dose Vial (15 mL) For single use only. Discard used vial, including any unused contents. After dilution, the solution is stable for a maximum of 4 hours at room temperature 20° to 25°C (68° to 77°F) or 14 days under refrigeration at 2° to 8°C (36° to 46°F). 2.2 Dosage for Administration in Intravenous Fluids to Correct Hypophosphatemia Potassium phosphates injection provides phosphorus 3 mmol/mL (potassium 4.4 mEq/mL). The dosage is dependent upon the individual needs of the patient and the contribution of phosphorus and potassium from other sources. Initial or Single-Dose The phosphorus doses in Table 2 are general recommendations for an initial or single-dose and are intended for most patients. Based upon clinical requirements, some patients may require a lower or higher dose. The maximum initial or single-dose of phosphorus is 45 mmol (potassium 66 mEq) [see Warnings and Precautions (5.1) ] . In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m 2 to < 60 mL/min/1.73 m 2 ), start at the low end of the dose range [see Use in Specific Populations (8.6) ] . Monitor serum phosphorus, potassium, calcium and magnesium serum concentrations. Table 2: Recommended Initial or Single-Dose of Potassium Phosphates Injection in Intravenous Fluids to Correct Hypophosphatemia in Adults and Pediatric Patients Serum Phosphorus Concentration a Phosphorus Dosage b, c Corresponding Potassium Content 1.8 mg/dL to lower end of the reference range a 0.16 mmol/kg to 0.31 mmol/kg potassium 0.23 mEq/kg to 0.46 mEq/kg 1 mg/dL to 1.7 mg/dL 0.32 mmol/kg to 0.43 mmol/kg potassium 0.47 mEq/kg to 0.63 mEq/kg Less than 1 mg/dL 0.44 mmol/kg to 0.64 mmol/kg c potassium 0.64 mEq/kg to 0.94 mEq/kg a Serum phosphorus reported using 2.5 mg/dL as the lower end of the reference range for healthy adults and pediatric patients 12 months of age and older. Serum phosphorus reported using 4 mg/dL as the lower end of the reference range for preterm and term infants less than 12 months of age. Serum phosphorus concentrations may vary depending on the assay used and the laboratory reference range. b Weight is in terms of actual body weight. Limited information is available regarding dosing of patients significantly above ideal body weight; consider using an adjusted body weight for these patients. c up to a maximum of phosphorus 45 mmol (potassium 66 mEq) as a single-dose. Concentration and Intravenous Infusion Rate The concentration of the diluted solution [see Table 1, Dosage and Administration (2.1) ] and the infusion rate is dependent upon whether administration will be through a peripheral or central venous catheter. The maximum recommended infusion rates are shown in Table 3 for adults and pediatric patients 12 years of age and older. Table 3: Maximum Recommended Infusion Rate of Potassium Phosphates Injection for Adults and Pediatric Patients 12 Years of Age and Older Route of Administration Maximum Infusion Rate Peripheral Venous Catheter phosphorus 6.8 mmol/hour (potassium 10 mEq/hour) Central Venous Catheter phosphorus 15 mmol/hour (potassium 22 mEq/hour) Continuous electrocardiographic (ECG) monitoring and infusion through a central venous catheter is recommended for infusion rates higher than: Potassium 10 mEq/hour for adults and pediatric patients weighing 20 kg or greater. Potassium 0.5 mEq/kg/hour for pediatric patients weighing less than 20 kg. Repeated Dosing Additional dose(s) following the initial dose may be needed in some patients. Prior to administration of additional doses, assess the patient clinically, obtain serum phosphorus, calcium and potassium concentrations and adjust the dose accordingly. 2.3 Preparation and Administration in Parenteral Nutrition Potassium phosphates injection is for intravenous infusion into a peripheral or central vein only after dilution and admixing . Potassium phosphates injection is to be prepared only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). The key factor in the preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and addition of other nutrients. Transfer the required amount of potassium phosphates injection to the parenteral nutrition solution following the admixture of amino acids, dextrose, electrolytes solutions and prior to lipids (if added). Because additives may be incompatible, evaluate all additions to the parenteral nutrition container for compatibility and stability of the resulting preparation. Calcium and phosphate ratios must be considered. Excess addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of calcium-phosphate precipitates [see Warnings and Precautions (5.2) ] . Calcium-phosphate stability in parenteral nutrition solutions is dependent upon the pH of the solution, temperature and relative concentration of each ion. Discard if any precipitates are observed. Inspect the final parenteral solution containing potassium phosphates injection to ensure that: precipitates have not formed during mixing or addition of additives and inspect again before administration. the emulsion has not separated, if lipids have been added. Separation of the emulsion can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the admixed emulsion. The final parenteral nutrition solution is for intravenous infusion into a peripheral or central vein. The choice of a peripheral or central venous route should depend on the osmolarity of the final infusate. Solutions with osmolarity of 900 mOsmol/L or greater must be infused through a central catheter [see Warnings and Precautions (5.7) ] . Storage Protect the parenteral nutrition solution from light during storage. Stability Single-Dose Vial (15 mL) For single use only. Discard used vial, including any unused contents. Use parenteral nutrition solution containing potassium phosphates injection promptly after mixing. Any storage of the admixture should be under refrigeration from 2° to 8°C (36° to 46°F) and limited to a brief period of time, no longer than 24 hours. After removal from refrigeration, bring to room temperature and use promptly and complete the infusion within 24 hours. Discard any remaining admixture. 2.4 Dosage for Administration in Parenteral Nutrition Potassium phosphates injection provides phosphorus 3 mmol/mL (potassium 4.4 mEq/mL). The recommended daily dosage in parenteral nutrition is shown in Table 4. Individualize the dosage based upon the patient’s clinical condition, nutritional requirements and the contribution of oral or enteral phosphorus and potassium intake. The amount of phosphorus that can be added to parenteral nutrition may be limited by the amount of calcium that is also added to the solution. Table 4: Recommended Daily Dosage of Potassium Phosphates Injection for Parenteral Nutrition for Adults and Pediatric Patients Patient Population Generally Recommended Phosphorus Daily Dosage (Potassium Content) Preterm and Term Infants Less than 12 Months 2 mmol/kg/day (potassium 2.9 mEq/kg/day) Pediatric Patients 1 year to Less Than 12 years 1 mmol/kg/day; up to 40 mmol/day (potassium 1.5 mEq/kg/day; up to 58.7 mEq/day) Adults and Pediatric Patients 12 Years of Age and Older 20 mmol/day to 40 mmol/day a (potassium 29.3 mEq/day to 58.7 mEq/day) a In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m 2 to < 60 mL/min/1.73 m 2 ), start at the low end of the dosage range. Monitoring Monitor serum phosphorus, potassium, calcium and magnesium concentrations and adjust the dosage accordingly."],"spl_product_data_elements":["POTASSIUM PHOSPHATES potassium phosphate, monobasic potassium phosphate, dibasic injection, POTASSIUM PHOSPHATE, MONOBASIC POTASSIUM CATION PHOSPHATE ION POTASSIUM PHOSPHATE, DIBASIC POTASSIUM CATION PHOSPHATE ION WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Potassium phosphates injection, USP is a sterile clear, colorless solution supplied as: phosphorus 45 mmol/15 mL (3 mmol/mL) and potassium 66 mEq/15 mL (4.4 mEq/mL) in a single-dose vial. Injection: phosphorus 45 mmol/15 mL (3 mmol/mL) and potassium 66 mEq/15 mL (4.4 mEq/mL) in a single-dose vial. ( 3 )"],"use_in_specific_populations":["8 USES IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with potassium phosphates injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo-Fetal Risk Phosphorus is an essential mineral element. Parenteral supplementation with potassium phosphates should be considered if a pregnant woman’s requirements cannot be fulfilled by oral or enteral intake. 8.2 Lactation Risk Summary Phosphorus and potassium are present in human milk. Administration of the recommended dose of potassium phosphates injection is not expected to cause harm to a breastfed infant. There is no information on the effects of potassium phosphates on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for potassium phosphates injection and any potential adverse effects on the breastfed child from potassium phosphates injection or from underlying maternal condition. 8.4 Pediatric Use Safety and effectiveness of potassium phosphates injection have been established in pediatric patients as a source of phosphorus: in intravenous fluids to correct hypophosphatemia when oral or enteral replacement is not possible, insufficient, or contraindicated. for parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated. Because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with potassium phosphates injection may be at higher risk of aluminum toxicity [see Warnings and Precautions (5.5) ] . 8.5 Geriatric Use In general, dose selection of potassium phosphates injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. It may be useful to monitor renal function during treatment [see Use in Specific Populations (8.6) ] . 8.6 Renal Impairment Potassium and phosphorus are known to be substantially excreted by the kidney and the risk of adverse reactions to potassium phosphates injection may be greater in patients with impaired renal function [see Warnings and Precautions (5.3 , 5.4 , 5.5) ] . Potassium phosphates injection is contraindicated due to the risk of hyperkalemia in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m 2 ) or end stage renal disease [see Contraindications (4) ] . In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m 2 to < 60 mL/min/1.73 m 2 ), start at the low end of the dosage range and monitor serum potassium, phosphorus, calcium and magnesium concentrations [see Dosage and Administration (2.2 , 2.4) ]."],"dosage_and_administration_table":["
Patient PopulationPeripheral Venous CatheterCentral Venous Catheter
Adults and Pediatric Patients 12 Years of Age and Olderphosphorus 6.8 mmol/100 mL (potassium 10 mEq/100 mL)phosphorus 18 mmol/100 mL (potassium 26.4 mEq/100 mL)
Pediatric Patients Less than 12 Years of Agephosphorus 0.27 mmol/10 mL (potassium 0.4 mEq/10 mL)phosphorus 0.55 mmol/10 mL (potassium 0.8 mEq/10 mL)
","
Serum Phosphorus ConcentrationaPhosphorus Dosageb, cCorresponding Potassium Content
1.8 mg/dL to lower end of the reference rangea0.16 mmol/kg to 0.31 mmol/kgpotassium 0.23 mEq/kg to 0.46 mEq/kg
1 mg/dL to 1.7 mg/dL0.32 mmol/kg to 0.43 mmol/kgpotassium 0.47 mEq/kg to 0.63 mEq/kg
Less than 1 mg/dL0.44 mmol/kg to 0.64 mmol/kgcpotassium 0.64 mEq/kg to 0.94 mEq/kg
a Serum phosphorus reported using 2.5 mg/dL as the lower end of the reference range for healthy adults and pediatric patients 12 months of age and older. Serum phosphorus reported using 4 mg/dL as the lower end of the reference range for preterm and term infants less than 12 months of age. Serum phosphorus concentrations may vary depending on the assay used and the laboratory reference range.b Weight is in terms of actual body weight. Limited information is available regarding dosing of patients significantly above ideal body weight; consider using an adjusted body weight for these patients.c up to a maximum of phosphorus 45 mmol (potassium 66 mEq) as a single-dose.
","
Route of AdministrationMaximum Infusion Rate
Peripheral Venous Catheterphosphorus 6.8 mmol/hour (potassium 10 mEq/hour)
Central Venous Catheterphosphorus 15 mmol/hour (potassium 22 mEq/hour)
","
Patient PopulationGenerally Recommended Phosphorus Daily Dosage (Potassium Content)
Preterm and Term Infants Less than 12 Months2 mmol/kg/day (potassium 2.9 mEq/kg/day)
Pediatric Patients 1 year to Less Than 12 years1 mmol/kg/day; up to 40 mmol/day (potassium 1.5 mEq/kg/day; up to 58.7 mEq/day)
Adults and Pediatric Patients 12 Years of Age and Older20 mmol/day to 40 mmol/daya (potassium 29.3 mEq/day to 58.7 mEq/day)
a In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 to < 60 mL/min/1.73 m2), start at the low end of the dosage range.
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 80830-1691-3 POTASSIUM PHOSPHATES INJECTION, USP Phosphorus 45 mmol/15 mL (3 mmol/mL) Potassium 66 mEq/15 mL (4.4 mEq/mL) 15 mL Vial Label Rx only Amneal Pharmaceuticals LLC NDC 80830-1691-9 POTASSIUM PHOSPHATES INJECTION, USP Phosphorus 45 mmol/15 mL (3 mmol/mL) Potassium 66 mEq/15 mL (4.4 mEq/mL) 10 x 15 mL Carton Label Rx only Amneal Pharmaceuticals LLC 2 5"]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"INFECTION","source":"FDA FAERS","actionTaken":"143 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"141 reports"},{"date":"","signal":"SLEEP DISORDER","source":"FDA FAERS","actionTaken":"139 reports"},{"date":"","signal":"PRODUCT USE ISSUE","source":"FDA FAERS","actionTaken":"129 reports"},{"date":"","signal":"TREATMENT FAILURE","source":"FDA FAERS","actionTaken":"116 reports"},{"date":"","signal":"RHEUMATOID ARTHRITIS","source":"FDA FAERS","actionTaken":"109 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"94 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"87 reports"},{"date":"","signal":"CONTRAINDICATED PRODUCT ADMINISTERED","source":"FDA FAERS","actionTaken":"68 reports"},{"date":"","signal":"PRODUCT USE IN UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"61 reports"}],"drugInteractions":[{"drug":"Potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, tacrolimus, cyclosporine","severity":"Severe","mechanism":"Concurrent use increases serum potassium concentration","management":"Avoid use if possible. If use cannot be avoided, closely monitor serum potassium concentrations.","clinicalEffect":"Severe and potentially fatal hyperkalemia, particularly with other hyperkalemia risk factors"}],"commonSideEffects":[{"effect":"Rash","drugRate":"20.0%","placeboRate":"","totalAtRisk":10,"totalAffected":2,"trialsReporting":1},{"effect":"Febrile neutropenia","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Conjunctivitis","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Abdominal pain upper","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Dyspepsia","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Nausea","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Oral pain","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Fungal skin infection","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Oral intake reduced","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Flank pain","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Anxiety","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Dysmenorrhoea","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Epistaxis","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Sneezing","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Dry skin","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Skin chapped","drugRate":"10.0%","placeboRate":"","totalAtRisk":10,"totalAffected":1,"trialsReporting":1},{"effect":"Constipation","drugRate":"0.0%","placeboRate":"","totalAtRisk":10,"totalAffected":0,"trialsReporting":1},{"effect":"Animal scratch","drugRate":"0.0%","placeboRate":"","totalAtRisk":10,"totalAffected":0,"trialsReporting":1},{"effect":"Ankle fracture","drugRate":"0.0%","placeboRate":"","totalAtRisk":10,"totalAffected":0,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"0.0%","placeboRate":"","totalAtRisk":10,"totalAffected":0,"trialsReporting":1},{"effect":"Insomnia","drugRate":"0.0%","placeboRate":"","totalAtRisk":10,"totalAffected":0,"trialsReporting":1},{"effect":"Dysuria","drugRate":"0.0%","placeboRate":"","totalAtRisk":10,"totalAffected":0,"trialsReporting":1},{"effect":"Dermatitis contact","drugRate":"0.0%","placeboRate":"","totalAtRisk":10,"totalAffected":0,"trialsReporting":1},{"effect":"Hypoaesthesia facial","drugRate":"0.0%","placeboRate":"","totalAtRisk":10,"totalAffected":0,"trialsReporting":1}],"contraindications":["Hyperkalemia","Severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or end stage renal disease","Hyperphosphatemia","Hypercalcemia or significant hypocalcemia"],"specialPopulations":{"Pregnancy":"Administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with potassium phosphates injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo-Fetal Risk Phosphorus is an essential mineral element. Parenteral supplementation with potassium phosphates should be considered if a pregnant woman’s requirements cannot be fulfilled by oral or enteral intake.","Geriatric use":"In general, dose selection of potassium phosphates injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. It may be useful to monitor renal function during treatment [see Use in Specific Populations (8.6) ] .","Paediatric use":"Safety and effectiveness of potassium phosphates injection have been established in pediatric patients as a source of phosphorus: in intravenous fluids to correct hypophosphatemia when oral or enteral replacement is not possible, insufficient, or contraindicated. for parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated. Because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with potassium phosphates injection may be at higher risk of aluminum toxicity [see Warnings and Precautions (5.5) ] .","Renal impairment":"Potassium and phosphorus are known to be substantially excreted by the kidney and the risk of adverse reactions to potassium phosphates injection may be greater in patients with impaired renal function. Potassium phosphates injection is contraindicated due to the risk of hyperkalemia in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m^2) or end stage renal disease. In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m^2 to < 60 mL/min/1.73 m^2), start at the low end of the dosage range and monitor serum potassium, phosphorus, calcium and magnesium concentrations.","Hepatic impairment":"Not mentioned"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_recalls":[{"date":"20170809","reason":"Lack of Sterility Assurance","classification":"Class II"},{"date":"20140416","reason":"Lack of Assurance of Sterility: The firm expanded the recall to other injectable products due to lack of assurance of sterility from poor aseptic practices observed at the firm.","classification":"Class II"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Potassium Phosphate, Dibasic","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:31:31.622676+00:00"},"mechanism":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:33:15.178513+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:31:37.590809+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:31:31.694518+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:31:30.748483+00:00"},"pharmacokinetics":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:33:15.178536+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Potassium Phosphate, Dibasic","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:31:38.288587+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:31:29.065049+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:31:29.065074+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:31:40.470414+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200459/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:31:39.615473+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA216344","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:31:29.065078+00:00"}},"allNames":"potassium phosphates","offLabel":[],"timeline":[{"date":"1993-06-10","type":"positive","_source":"FDA NDA019873","milestone":"FDA ORIG — B BRAUN","regulator":"FDA","description":""},{"date":"1994-06-01","type":"positive","_source":"FDA NDA019873","milestone":"FDA SUPPL — B BRAUN","regulator":"FDA","description":""},{"date":"1995-09-13","type":"positive","_source":"FDA NDA019873","milestone":"FDA SUPPL — B BRAUN","regulator":"FDA","description":""},{"date":"1998-08-21","type":"positive","_source":"FDA NDA019873","milestone":"FDA SUPPL — B BRAUN","regulator":"FDA","description":""},{"date":"2000-05-15","type":"positive","_source":"FDA NDA019873","milestone":"FDA SUPPL — B BRAUN","regulator":"FDA","description":""},{"date":"2002-04-15","type":"positive","_source":"FDA NDA019873","milestone":"FDA SUPPL — B BRAUN","regulator":"FDA","description":""},{"date":"2004-05-11","type":"positive","_source":"FDA NDA019873","milestone":"FDA SUPPL — B BRAUN","regulator":"FDA","description":""},{"date":"2019-11-26","type":"positive","_source":"FDA NDA212832","milestone":"FDA ORIG — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2023-10-02","type":"positive","_source":"FDA ANDA216274","milestone":"FDA ORIG — AM REGENT","regulator":"FDA","description":""},{"date":"2023-10-10","type":"positive","_source":"FDA ANDA216344","milestone":"FDA ORIG — AMNEAL","regulator":"FDA","description":""},{"date":"2024-07-26","type":"positive","_source":"FDA NDA218343","milestone":"FDA ORIG — AMNEAL","regulator":"FDA","description":""},{"date":"2024-08-30","type":"positive","_source":"FDA NDA212832","milestone":"FDA SUPPL — FRESENIUS KABI USA","regulator":"FDA","description":""},{"date":"2025-01-24","type":"positive","_source":"FDA ANDA217892","milestone":"FDA ORIG — CIPLA","regulator":"FDA","description":""},{"date":"2025-01-30","type":"positive","_source":"FDA ANDA216274","milestone":"FDA SUPPL — AM REGENT","regulator":"FDA","description":""},{"date":"2025-02-19","type":"positive","_source":"FDA ANDA216344","milestone":"FDA SUPPL — AMNEAL","regulator":"FDA","description":""},{"date":"2025-09-11","type":"positive","_source":"FDA ANDA217459","milestone":"FDA ORIG — HOSPIRA","regulator":"FDA","description":""},{"date":"2026-03-12","type":"positive","_source":"FDA ANDA220373","milestone":"FDA ORIG — CAPLIN","regulator":"FDA","description":""}],"_dailymed":{"setId":"16ecc94f-1001-983c-e063-6294a90a7b6c","title":"COMPLETE 30C/200C HOMEOPATHIC KIT (100 REMEDY KIT) KIT [WASHINGTON HOMEOPATHIC PRODUCTS]","labeler":""},"aiSummary":"Potassium phosphates injection is an inorganic phosphate replacement indicated for hypophosphatemia correction and parenteral nutrition in adults and pediatric patients. The drug is contraindicated in hyperkalemia, severe renal impairment, hyperphosphatemia, and abnormal calcium levels. Significant drug interactions exist with potassium-elevating agents requiring careful monitoring or avoidance. Renal function and serum electrolytes must be closely monitored during therapy.","brandName":"Potassium Phosphates","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Phosphorus homeostasis and cellular biochemical functions","novelty":"Best-in-class","modality":"Inorganic phosphate salt","drugClass":"Electrolyte replacement","explanation":"Phosphorus in the form of inorganic phosphate has critical biochemical functions in all organs and tissues. These functions include roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis and bone mineralization. The drug provides exogenous phosphorus to correct deficiency states when oral or enteral replacement is not feasible.","oneSentence":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization.","technicalDetail":"Potassium Phosphates is a dibasic salt of potassium phosphate, which means it contains two phosphate groups. This molecular structure allows it to provide a sustained release of potassium ions. The drug is typically administered orally or intravenously, depending on the patient's needs. In patients with impaired renal function, Potassium Phosphates may be given more frequently to ensure adequate potassium levels."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","launchDate":"1993","annualCostUS":"$118.35","_launchSource":"FDA NDA019873 (B BRAUN)","genericStatus":"Generic — off-patent","currentRevenue":"","manufacturerCount":"4 approved manufacturers","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":""},"references":[{"id":1,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Potassium Phosphate, Dibasic","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Potassium%20Phosphate%2C%20Dibasic","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Potassium Phosphate, Dibasic","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/","fields":["timeline","launchDate"],"source":"FDA Drugs@FDA"},{"id":6,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":7,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":8,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"},{"id":9,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/","fields":["genericManufacturers"],"source":"FDA Drugs@FDA (ANDA/BLA)"}],"_tgaChecked":true,"_validation":{"fieldsValidated":7,"lastValidatedAt":"2026-04-20T08:33:17.654793+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Fructose 1,6-diphosphate","company":"Multiple","advantage":"Organic phosphate source"},{"name":"Disodium glucose-1-phosphate","company":"Multiple","advantage":"Organic phosphate option"},{"name":"Sodium glycerophosphate","company":"Multiple","advantage":"Alternative organic phosphate salt that can be used, though it may not be registered"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"potassium phosphate, dibasic","indications":{"approved":[{"name":"Treatment of potassium deficiency (hypokalemia) in patients with normal renal function.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with impaired renal function.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium-wasting nephropathy.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium-wasting renal tubular acidosis.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium-wasting conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hyperaldosteronism.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with Cushing's syndrome.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with primary aldosteronism.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hyperthyroidism.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hyperparathyroidism.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with gastrointestinal disorders.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with diarrhea.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with vomiting.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with nasogastric suction.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium loss due to medications.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with potassium loss due to other conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to medications.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other reasons.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other reasons.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other reasons.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other reasons.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other reasons.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other reasons.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other reasons.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other reasons.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other reasons.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other medical conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other factors.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other causes.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other reasons.","regulator":"FDA"},{"name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other underlying conditions.","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_drugWebsite":{"url":"https://www.potassiumphosphates.com","content":" \n \n POTASSIUM PHOSPHATES- monobasic potassium phosphate and dibasic potassium phosphate injection \nCMP PHARMA, INC.\n \n---------- \n \n \n \nHIGHLIGHTS OF PRESCRIBING INFORMATION \nThese highlights do not include all the information needed to use POTASSIUM PHOSPHATES INJECTION safely and effectively. See full prescribing information for POTASSIUM PHOSPHATES INJECTION. \n \nPOTASSIUM PHOSPHATES injection, for intravenous use\nInitial U.S. Approval: 1983 \n \n \n INDICATIONS AND USAGE \n \nPOTASSIUM PHOSPHATES INJECTION is a phosphorus replacement product indicated as a source of phosphorus: (1) \n \nin intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older when oral or enteral replacement is not possible, insufficient or contraindicated. (1.1) \nfor parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or contraindicated. (1.2) \n \n Limitations of Use: Safety has not been established for parenteral nutrition in adults weighing less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due to the risk of aluminum toxicity. (1.2, 5.5, 8.4) \n \n \n \n DOSAGE AND ADMINISTRATION \n \n \nAdminister intravenously only after dilution or admixing in a larger volume of fluid. (2.1) \nPOTASSIUM PHOSPHATES INJECTION provides phosphorus 3 mmol/mL (potassium 4.7 mEq/mL). (2.2, 2.4) \nMonitor serum phosphorus, potassium, calcium, and magnesium concentrations. (2.2, 2.4) \nSee full prescribing information for instructions on preparation and administration. (2.1, 2.3) \n Recommended Dosage for Correction of Hypophosphatemia in Intravenous Fluids: (2) \n \nPOTASSIUM PHOSPHATES INJECTION is only for administration to a patient with a serum potassium concentration less than 4 mEq/dL; otherwise, use an alternative source of phosphate. (2.1) \nThe dosage is dependent upon the individual "},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06750653","phase":"PHASE4","title":"Skin Barrier Function and Inflammation in Aging: The BIA Study","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-02-06","conditions":"Inflammation, Skin Inflammation, Aging","enrollment":32},{"nctId":"NCT07189091","phase":"PHASE4","title":"CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2025-10-07","conditions":"Critical Care, Intensive Care, Fluid Accumulation, Fluid and Electrolyte Imbalance","enrollment":640},{"nctId":"NCT05501756","phase":"PHASE2","title":"Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-01-11","conditions":"Allogeneic Hematopoietic Cell Transplantation","enrollment":60},{"nctId":"NCT06800131","phase":"PHASE1","title":"Hepatitis B Vaccine Delivered Trans-dermally by MAP","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-02-05","conditions":"Hepatitis B Vaccine","enrollment":40},{"nctId":"NCT06126094","phase":"NA","title":"Benefits of Alcoholic Hangover Medicine","status":"UNKNOWN","sponsor":"The Gut Microbiome Center (Centar za crijevni mikrobiom)","startDate":"2023-10-31","conditions":"Gastrointestinal Microbiome","enrollment":2},{"nctId":"NCT04026438","phase":"PHASE4","title":"Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT)","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2019-01-21","conditions":"Complication, Postoperative, Regeneration Liver","enrollment":130},{"nctId":"NCT02866435","phase":"EARLY_PHASE1","title":"Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2016-11","conditions":"Hypoglycemia","enrollment":27},{"nctId":"NCT02956070","phase":"NA","title":"Anti-inflammatory Steroids in the Prevention of Tooth Sensitivity","status":"COMPLETED","sponsor":"Universidade Federal Fluminense","startDate":"2015-10","conditions":"Inflammation","enrollment":70},{"nctId":"NCT03992365","phase":"PHASE3","title":"Study of the Efficacy and Safety of Quiklean® and Klean-Prep With Dulcolax® for the Bowel Preparation Prior to Colonoscopy","status":"COMPLETED","sponsor":"Universal Integrated Corp.","startDate":"2019-06-10","conditions":"Bowel Preparation","enrollment":472},{"nctId":"NCT00691652","phase":"PHASE1, PHASE2","title":"Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2008-05","conditions":"Lymphoma","enrollment":2},{"nctId":"NCT03302754","phase":"NA","title":"Precision Dosing of Alemtuzumab","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2017-10-05","conditions":"Allogeneic Hematopoietic Cell Transplantation","enrollment":12},{"nctId":"NCT00780286","phase":"PHASE1","title":"Evaluate Retention of an Orally Administered Device Using Gamma Scintigraphy Study 2","status":"COMPLETED","sponsor":"Procter and Gamble","startDate":"2008-10","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT03611283","phase":"NA","title":"Topical Management of Xerostomia With Dry Mouth Products","status":"COMPLETED","sponsor":"Rosa María López-Pintor Muñoz","startDate":"2016-10-03","conditions":"Xerostomia, Sjogren's Syndrome","enrollment":28},{"nctId":"NCT00112112","phase":"PHASE1","title":"Safety Study to Evaluate FluMist in Immunocompromised Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2005-08-01","conditions":"Cancer","enrollment":20},{"nctId":"NCT02594787","phase":"NA","title":"The Effect of Phosphorus on Diet Induced Thermogenesis","status":"COMPLETED","sponsor":"Lebanese American University","startDate":"2011-03","conditions":"Imbalance of Constituents of Food Intake, Healthy","enrollment":23},{"nctId":"NCT01889173","phase":"PHASE1","title":"Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2013-06","conditions":"Healthy Adults","enrollment":24},{"nctId":"NCT00482027","phase":"PHASE1","title":"Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine","status":"COMPLETED","sponsor":"International AIDS Vaccine Initiative","startDate":"2003-12","conditions":"HIV Infection","enrollment":80},{"nctId":"NCT01676844","phase":"PHASE2","title":"Investigating a New Way of Giving Medicine to Newborn and Preterm Babies","status":"UNKNOWN","sponsor":"University of Strathclyde","startDate":"2013-02","conditions":"Hypophosphataemia, Osteopenia of Prematurity","enrollment":20},{"nctId":"NCT00224783","phase":"PHASE1","title":"Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-08","conditions":"Healthy Japanese Male Adults","enrollment":45},{"nctId":"NCT00817934","phase":"","title":"Safe, Effective, and More Tolerable 16 Tablets Colon Prep","status":"UNKNOWN","sponsor":"Long Neck Medical Enterprises","startDate":"2009-01","conditions":"Colon Cancer","enrollment":400},{"nctId":"NCT00004284","phase":"PHASE3","title":"Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1995-04","conditions":"Hypercalciuria, Kidney Calculi","enrollment":300}],"_emaApprovals":[{"date":"","name":"Potassium Phosphates","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://glenmarkpharma.com/gpl_pdfs/media/Press%20Release%20-%20Glenmark%20Pharmaceuticals%20Inc.%2C%20USA%20to%20launch%20Potassium%20Phosphates%20Injection%20USP.pdf","date":"2026-04-07","type":"news","title":"[PDF] Glenmark Pharmaceuticals Inc., USA to launch","source":"glenmarkpharma.com"},{"url":"https://www.fortunebusinessinsights.com/phosphates-market-104570","date":"2026-04-07","type":"news","title":"Phosphate Market Size, Share, Trends | Growth Forecast [2034]","source":"www.fortunebusinessinsights.com"},{"url":"https://www.kpluss.com/en-us/newsroom/press-releases/financial-figures-in-line-with-expectations/","date":"2026-04-07","type":"news","title":"Financial figures in line with expectations | K+S Aktiengesellschaft","source":"www.kpluss.com"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212832Orig1s000ChemR.pdf","date":"2026-04-07","type":"news","title":"[PDF] 212832Orig1s000 - accessdata.fda.gov","source":"www.accessdata.fda.gov"},{"url":"https://www.fda.gov/drugs/unapproved-drugs/fda-notification-regarding-potassium-phosphates-injection","date":"2026-04-07","type":"news","title":"FDA notification regarding potassium phosphates injection","source":"www.fda.gov"}],"manufacturing":[{"role":"Manufacturer","site":"Amneal Pharmaceuticals Private Limited","location":"","operator":"Amneal Pharmaceuticals Private Limited"}],"molecularData":{"oral":false,"chemblId":"CHEMBL1200459","moleculeType":"Small molecule","molecularWeight":"174.17"},"administration":{"route":"Intravenous","formulation":"alanine 8.8 MG/ML / arginine 4.89 MG/ML / calcium chloride 0.004 MEQ/ML / dibasic potassium phosphate 2.61 MG/ML / glucose 100 MG/ML / glycine 4.38 MG/ML / histidine 2.04 MG/ML / isoleucine 2.55 MG/ML / leucine 3.11 MG/ML / lysine 2.47 MG/ML / magnesium chloride 0.01 MEQ/ML / methionine 1.7 MG/ML / phenylalanine 2.38 MG/ML / proline 2.89 MG/ML / serine 2.13 MG/ML / sodium acetate trihydrate 2.97 MG/ML / sodium chloride 0.013 MEQ/ML / threonine 1.79 MG/ML / tryptophan 0.77 MG/ML / tyrosine 0.17 MG/ML / valine 2.47 MG/ML Injectable Solution [Clinimix E 4.25/10]; dibasic potassium phosphate 1 MG/ML / glucose 50 MG/ML / magnesium chloride 0.00639 MEQ/ML / potassium chloride 0.0134 MEQ/ML / sodium chloride 0.0308 MEQ/ML / sodium lactate 0.025 MEQ/ML / sodium phosphate, monobasic 0.16 MG/ML Injectable Solution [Ionosol-B]; dibasic potassium phosphate 0.26 MG/ML / glucose 50 MG/ML / magnesium chloride 0.00373 MEQ/ML / potassium chloride 0.00174 MEQ/ML / sodium acetate 0.039 MEQ/ML Injectable Solution [Isolyte P]"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"unii":"CI71S98N1Z","rxcui":"55018","splId":"9256cc7f-e593-4224-8b44-19e8d01d2cb4","chemblId":"CHEMBL1200459","pubchemSID":"50070033"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1993-present","_source":"FDA label","companyName":"B BRAUN","relationship":"Originator"}],"pharmacokinetics":{"tmax":"","halfLife":"","clearance":"","excretion":"Intravenously infused phosphates not taken up by tissues are excreted almost entirely in urine. Serum phosphorus is filterable by renal glomeruli with greater than 80% of filtered phosphorus actively reabsorbed by tubules.","metabolism":"","proteinBinding":"15% protein-bound; approximately 85% free and ultra-filterable","bioavailability":"","volumeOfDistribution":""},"publicationCount":23,"therapeuticAreas":["Nephrology"],"biosimilarFilings":[],"commercialAnalysis":{"text":"**Commercial Analysis: Potassium Phosphates (Potassium Phosphate, Dibasic) by Pfizer**\n\nThe current market position of Potassium Phosphates (Potassium Phosphate, Dibasic) by Pfizer is uncertain, as the revenue data for this specific product is not provided in the given sources. However, the global phosphate market size was valued at USD 180.60 billion in 2025, with a projected growth rate of 5.6% from 2026 to 2034 [1]. This indicates a potential increase in demand for potassium phosphates, which could positively impact Pfizer's revenue.\n\nThe competitive landscape for potassium phosphates is dynamic, with Glenmark Pharmaceuticals Inc., USA launching its own version of the product in March 2026 [2]. This launch is expected to increase competition in the market, potentially affecting Pfizer's market share. According to IQVIA sales data, the Potassium Phosphates Injection USP market achieved annual sales of approximately $50.7 million in the 12-month period ending January 2026 [2].\n\nKey upcoming catalysts for the potassium phosphates market include the potential patent cliff and label expansions. However, specific information on these catalysts is not provided in the given sources. Additionally, the pipeline for competitors is not detailed in the sources.\n\nThe market outlook for potassium phosphates is positive, driven by the growing demand for phosphate-based products. However, the impact of Glenmark's launch and potential patent cliffs on Pfizer's revenue is uncertain. Further research is needed to provide a more comprehensive analysis of the market.\n\nReferences:\n[1] Fortune Business Insights, \"Phosphate Market Size, Share & Industry Analysis, By Product Type (Ammonium, Calcium, Phosphoric Acid, Potassium, Sodium, and Others), By Application (Agrochemicals, Food & Beverages, Animal Feed, Detergent & Cleaning, Water Treatment Chemicals, and Others), and Regional Forecast, 2026-2034\" [2] Glenmark Pharmaceuticals Inc., USA, \"Glenmark Pharmaceuticals Inc., USA to launch Potassium Phosphates Injection USP\"","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://glenmarkpharma.com/gpl_pdfs/media/Press%20Release%20-%20Glenmark%20Pharmaceuticals%20Inc.%2C%20USA%20to%20launch%20Potassium%20Phosphates%20Injection%20USP.pdf","date":"","title":"[PDF] Glenmark Pharmaceuticals Inc., USA to launch","source":"glenmarkpharma.com"},{"url":"https://www.fortunebusinessinsights.com/phosphates-market-104570","date":"","title":"Phosphate Market Size, Share, Trends | Growth Forecast [2034]","source":"www.fortunebusinessinsights.com"},{"url":"https://www.kpluss.com/en-us/newsroom/press-releases/financial-figures-in-line-with-expectations/","date":"","title":"Financial figures in line with expectations | K+S Aktiengesellschaft","source":"www.kpluss.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"date":"2026 Mar","pmid":"41749492","title":"Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy Volunteers.","journal":"Clinical pharmacology in drug development"},{"date":"2025 Jul 18","pmid":"40681738","title":"Development of a novel Agarose/Nano-Hydroxyapatite/Grape seed extract hydrogel for biomimetic remineralization of demineralized human enamel (An In-Vitro Study).","journal":"Scientific reports"},{"date":"2024 Mar 27","pmid":"38666831","title":"Nanoparticles and Chemical Inducers: A Sustainable Shield against Onion White Rot.","journal":"Biology"},{"date":"2022 Jun 16","pmid":"35741979","title":"Development of Simultaneous Analytical Method for Imidazolinone Herbicides from Livestock Products by UHPLC-MSMS.","journal":"Foods (Basel, Switzerland)"},{"date":"2021 Oct 19","pmid":"34618420","title":"High-Throughput Method for Natural Organic Matter Hydrophobicity Assessment Using an Ionic Liquid-Based Aqueous Two-Phase System.","journal":"Environmental science & technology"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"genericManufacturers":["B BRAUN","FRESENIUS KABI USA","AMNEAL","AM REGENT"],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1993","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-12-07T00:00:00.000Z","mah":"B BRAUN","brand_name_local":null,"application_number":"NDA019873"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-10-10T00:00:00.000Z","mah":"AMNEAL","brand_name_local":null,"application_number":"ANDA216344"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-08-30T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"NDA212832"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-01-30T00:00:00.000Z","mah":"AM REGENT","brand_name_local":null,"application_number":"ANDA216274"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"118.35","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":5,"withResults":1},"validation":{"fieldsValidated":7,"lastValidatedAt":"2026-04-20T08:33:17.654793+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}